Acute Myeloid Leukaemia (AML)
Description:
Available tests
Karyotyping;
Fluorescence in situ hybridisation for:
-AML1-ETO to detect t(8;21);
-PML-RARα to detect t(15;17);
-RARα to detect variant RARα rearrangements;
-CBFβ to detect inv(16)/t(16;16);
-MLL to detect 11q23 rearrangement;
-D5S23,D5S721/EGR1 to detect del(5q31)/-5;
-D7S486/CEP7 to detect del(7q31)/-7;
-D20S108 to detect del(20q);
-Chromosome 8 Alpha satellite to detect trisomy 8;
-EVI to detect inv(3)/t(3;3);
Karyotyping;
Fluorescence in situ hybridisation for:
-AML1-ETO to detect t(8;21);
-PML-RARα to detect t(15;17);
-RARα to detect variant RARα rearrangements;
-CBFβ to detect inv(16)/t(16;16);
-MLL to detect 11q23 rearrangement;
-D5S23,D5S721/EGR1 to detect del(5q31)/-5;
-D7S486/CEP7 to detect del(7q31)/-7;
-D20S108 to detect del(20q);
-Chromosome 8 Alpha satellite to detect trisomy 8;
-EVI to detect inv(3)/t(3;3);
Clinical details:
A number of sub-types of acute myeloid leukaemia are characterised by specific cytogenetic abnormalities, some of which have now been incorprorated into the WHO classification of AML and related precursor neoplasms. Current NCRI trial protocols for AML also incorporate these cytogenetic abnormalities in risk stratification of patients; consequently cytogenetic analysis at diagnosis is critical for optimum patient management, and these abnormalities are also then used to assess remission status and in disease monitoring.
Synonyms or keywords:
Acute myeloid leukaemia, AML, AML1-ETO, t(8;21), RUNX1-RUNXT1, PML-RARα, t(15;17) RARα, CBFβ, MYH11, inv(16), t(16;16), MLL, 11q23, EGR1, del(5q), del(7q), monosomy 7, del(20q), Trisomy 8, EVI1, inv(3), t(3;3), PDGFRβ
Department:
Location:
Sample type and Volume required:
Peripheral blood, bone marrow aspirate, pleural effusion, fine needle aspirate, as appropriate, minimum volume as available
Turnaround time:
Current service turnaround times: Urgent 1-7 calendar days; Non-urgent 5-10 calendar days; National targets: Urgent samples 95% reported within 14 days; Non-urgent 95% reported within 21 days
Storage and transport:
Peripheral blood in lithium heparin or bone marrow transport medium. All other samples in bone marrow transport medium. Do not spindown or freeze samples before sending. Samples must arrive within 24 hours
Contacts:
Oncology Cytogenetics Laboratory at Guy's Hospital
020 7188 1713
viapath.OncologyDutyScientist@nhs.net
Genetics Department
Tower Wing - 5th Floor
Guy's Hospital
Great Maze Pond
London SE1 9RT
Tower Wing - 5th Floor
Guy's Hospital
Great Maze Pond
London SE1 9RT
Laboratory:
Last updated: 10/02/2022
